DRUG DIVERSION BILL NEGOTIATIONS ON SALES REP SAMPLING
DRUG DIVERSION BILL NEGOTIATIONS ON SALES REP SAMPLING have moved towards an agreement on provisions of a proposed draft of House legislation sponsored by Rep. Dingell (D-Mich.). Pharmaceutical manufacturers and congressional staffs on Oct. 3 were said to be close to a compromise that could lead to a bill ready for consideration by Oct. 6. Early during the week of Sept. 29, Dingell offered a draft provision that would permit distribution of Rx drug samples by company sales personnel -- if the samples are requested in writing by physicians -- with strict storate, handling, and recordkeeping standards. The draft also provides criminal penalties and fines for violations of the requirements, particularly for bartering or otherwise diverting samples. The general counsels of the major drug makers met in New York on Oct. 2 to discuss the compromise provision. They agreed that negotiations should continue. On Oct. 3, the lawyers met again and concurred that their concerns had been addressed satisfactorily. The draft demonstrates Dingell's desire to move the bill before Congress adjourns. The Pharmaceutical Manufacturers Association has already adopted some of the compromise concepts in a voluntary code of standards for sampling. The primary concerns about Dingell's bill centered, in part, upon aspects of proposed penalties that involved company sanctions and enforcement provisions under the FD&C Act. Specially, the counsels argued that a CEO should not be culpable if a single salesman is corrupted. Dingell reportedly accepted their argument. Energy & Commerce Committee markup of the drug diversion bill (HR 4820), which had been tentatively scheduled for Sept. 30, has been postponed. If the Michigan Democrat can strike an agreement on the measure, he can introduce a clean bill on the House floor for passage under suspension of the rules; Sen. Matsunaga (D-Hawaii) or Sen. Broyhill (R-N.C.) could take a similar tack in the Senate. Such quick action will depend upon fashioning legislation that has the endorsement of all interested industry and professional parties. Currently, HR 4820 has the support of all groups but PMA, which objects only to the sample distribution provision. If Dingell must begin the legislative process all over again next year because PMA has rebuffed what he considers a major concession, it is expected he will push for legislation to ban completely the distribution of samples to physicians. If he has to start again, Dingell is also warning that he could hold a series of hearings involving a number of companies to investigate abuses of samples.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth